会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • ARF-P19, a novel regulator of the mammalian cell cycle
    • ARF-P19是哺乳动物细胞周期的新型调节剂
    • US06407062B1
    • 2002-06-18
    • US09480718
    • 2000-01-07
    • Charles J. SherrDawn QuelleMartine F. RousselFrederique ZindyJason D. Weber
    • Charles J. SherrDawn QuelleMartine F. RousselFrederique ZindyJason D. Weber
    • C07K1400
    • C07K14/4738A01K2217/05A01K2217/075A61K38/00A61K48/00C07K14/4703C07K2319/00
    • The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.
    • INK4A(MTS1,CDKN2)基因编码细胞周期蛋白D-依赖性激酶CDK4和CDK6的特异性抑制剂(InK4a-p16)。 InK4a-p16可以阻断这些激酶磷酸化视网膜母细胞瘤蛋白(pRb),从而阻止细胞周期的G1期退出。 涉及编码InK4a-p16,INK4A的基因的缺失和突变频繁发生在癌细胞中,意味着像pRb一样的INK4a-p16抑制了肿瘤的制备。 然而,完全不相关的蛋白质(ARF-p19)主要来自小鼠INK4A基因的替代阅读框架。 ARF-p19 cDNA(SEQ ID NO:1)在啮齿动物成纤维细胞中的表达诱导G1期和G2期停滞。 蛋白质编码序列的经济再利用在哺乳动物基因组中是没有先例的,INK4a-p16和ARF-p19的单位遗传可能反映了细胞周期控制中两种蛋白质的双重要求。